Comparing two oral medications for treating a skin fungal infection
Official title: Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor
Run by Khyber Teaching Hospital · NCT06922344 · Data updated 2026-11-12
This study is testing which of two oral antifungal medications, fluconazole or itraconazole, works better for treating pityriasis versicolor, a common skin fungal infection.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 106 (estimated) |
| Sponsor | Khyber Teaching Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Peshawar, KPK) |
| Status | Recruiting |
| Started | March 1, 2025 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | April 10, 2025 |
| Trial ID | NCT06922344 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with pityriasis versicolor who do not have any exclusionary health conditions.
✕Probably not a fit
Patients with chronic renal or liver disease, malignancy, or those undergoing chemotherapy or radiotherapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of two oral antifungal medications, fluconazole and itraconazole, in treating pityriasis versicolor, a common fungal skin infection. It aims to determine which of the two systemic treatments is more effective for patients suffering from this condition. The study will involve patients diagnosed with pityriasis versicolor and will exclude those with certain health conditions or recent antifungal treatments. The results could provide valuable insights into optimal treatment options for this skin condition.
Why it matters
Potential benefit: If successful, this study could help identify the more effective treatment for pityriasis versicolor, improving patient outcomes.
How similar studies have gone: Other studies have explored the efficacy of antifungal treatments, but this specific comparison of fluconazole and itraconazole is less common, making it a valuable investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All cases of Pityriasis versicolor Exclusion Criteria: * Patients with history of chronic renal or liver disease, malignancy , or undergoing any kind of chemotherapy or radiotherapy or having cardiac conduction abnormalities. * Patients who received any anti-fungal therapy in the last one month. * Pregnant or lactating women.
Where it's running
-
Khyber Teaching Hospital
Peshawar, Kpk, Pakistan Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
20% Cassia alata cream for treating tinea versicolor
This trial will see if applying a 20% Cassia alata cream twice daily can clear tinea versicolor in adults aged 18–89.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.